Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy

被引:0
作者
Parisa Bakhshi
Maryam Nourizadeh
Laleh Sharifi
Mohammad M. Farajollahi
Monireh Mohsenzadegan
机构
[1] Iran University of Medical Sciences (IUMS),Department of Medical Biotechnology, School of Allied Medical Sciences
[2] Tehran University of Medical Sciences,Immunology, Asthma and Allergy Research Institute
[3] Tehran University of Medical Sciences,Uro
[4] Iran University of Medical Sciences (IUMS),Oncology Research Center
来源
Cancer Cell International | / 23卷
关键词
Dendritic cell vaccine; Immunotherapy; MAGE-A2; Long peptide; Prostate cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 69 条
[11]  
Gordeeva O(2018)Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs Clin Epigenet 15 28-312
[12]  
Shires K(2010)Expression of cancer/testis antigens in prostate cancer is associated with disease progression Prostate 38 1033-5040
[13]  
Van Wyk T(2022)Cancer vaccines as promising immuno-therapeutics: platforms and current progress J Hematol Oncol 106 6730-944
[14]  
Raghavendra A(2008)Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation Eur J Immunol 21 298-135
[15]  
Djureinovic D(2009)Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity Proc Natl Acad Sci 179 5033-237
[16]  
Weon JL(2021)Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion Nat Rev Cancer 5 905-2282
[17]  
Potts PR(2007)CD8 + CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity J Immunol 62 125-221
[18]  
Poojary M(2022)Peptides for vaccine development ACS Appl Bio Mater 9 225-969
[19]  
Jishnu PV(2013)Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma Cancer Immunol Immunother 7 2267-1161
[20]  
Kabekkodu SP(2014)In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC Target Oncol 15 217-6484